Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval

Executive Summary

Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen

You may also be interested in...



Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

Roche Stands Firm On Mergers, Says Now Is Not The Time To Bulk Up

Roche is committed to growing as a "focused high-tech health company" and sees no need to pursue a large merger at this time, Chief Financial Officer Erich Hunziker said during the company's year-end conference call Feb. 4

Related Content

UsernamePublicRestriction

Register

PS041872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel